The new single-use commercial facility will be among India’s largest, featuring advanced technologies to produce high-quality biologics and specialty pharmaceuticals
The company also reported significant progress toward its internally defined Sustainable Development Goals
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
The state-of-the-art facility is expected to be commissioned over the next three years
The state-of-the-art facility is a 350-bedded, multi-specialty tertiary care hospital
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA
Dr. Reddy's commits to achieving Net Zero greenhouse gas emissions across its value chain by FY 2045
This approval confirms the facility's compliance with FDA quality standards and regulatory requirements
Subscribe To Our Newsletter & Stay Updated
